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Design characteristics, risk of bias, and reporting of randomised 
controlled trials supporting approvals of cancer drugs by 
 European Medicines Agency, 2014-16: cross sectional analysis
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ABSTRACT
OBJECTIVE
To examine the design characteristics, risk of bias, 
and reporting adequacy of pivotal randomised 
controlled trials of cancer drugs approved by the 
European Medicines Agency (EMA).
DESIGN
Cross sectional analysis.
SETTING
European regulatory documents, clinical trial 
registry records, protocols, journal publications, and 
supplementary appendices.
ELIGIBILITY CRITERIA
Pivotal randomised controlled trials of new cancer 
drugs approved by the EMA between 2014 and 2016.
MAIN OUTCOME MEASURES
Study design characteristics (randomisation, 
comparators, and endpoints); risk of bias using 
the revised Cochrane tool (bias arising from the 
randomisation process, deviations from intended 
interventions, missing outcome data, measurement 
of the outcome, and selection of the reported 
result); and reporting adequacy (completeness 
and consistency of information in trial protocols, 
publications, supplementary appendices, clinical trial 
registry records, and regulatory documents).
RESULTS
Between 2014 and 2016, the EMA approved 32 new 
cancer drugs on the basis of 54 pivotal studies. Of 
these, 41 (76%) were randomised controlled trials 
and 13 (24%) were either non-randomised studies 
or single arm studies. 39/41 randomised controlled 
trials had available publications and were included 
in our study. Only 10 randomised controlled trials 
(26%) measured overall survival as either a primary 
or coprimary endpoint, with the remaining trials 
evaluating surrogate measures such as progression 
free survival and response rates. Overall, 19 
randomised controlled trials (49%) were judged to be 
at high risk of bias for their primary outcome. Concerns 
about missing outcome data (n=10) and measurement 
of the outcome (n=7) were the most common 
domains leading to high risk of bias judgments. Fewer 
randomised controlled trials that evaluated overall 
survival as the primary endpoint were at high risk 
of bias than those that evaluated surrogate efficacy 
endpoints (2/10 (20%) v 16/29 (55%), respectively). 
When information available in regulatory documents 
and the scientific literature was considered separately, 
overall risk of bias judgments differed for eight 
randomised controlled trials (21%), which reflects 
reporting inadequacies in both sources of information. 
Regulators identified additional deficits beyond the 
domains captured in risk of bias assessments for 10 
drugs (31%). These deficits included magnitude of 
clinical benefit, inappropriate comparators, and non-
preferred study endpoints, which were not disclosed as 
limitations in scientific publications.
CONCLUSIONS
Most pivotal studies forming the basis of EMA 
approval of new cancer drugs between 2014 and 
2016 were randomised controlled trials. However, 
almost half of these were judged to be at high risk 
of bias based on their design, conduct, or analysis, 
some of which might be unavoidable because of the 
complexity of cancer trials. Regulatory documents and 
the scientific literature had gaps in their reporting. 
Journal publications did not acknowledge the key 
limitations of the available evidence identified in 
regulatory documents.
Introduction
Regulatory agencies are responsible for evaluating 
the clinical efficacy and safety of new medicines. In 
the European Union, the European Medicines Agency 
(EMA) serves as the gatekeeper to the pharmaceutical 
market; clinicians can only prescribe a new drug 
after it receives the EMA’s approval.1 The EMA bases 
its decisions on a small number of key clinical 
studies completed and submitted by pharmaceutical 
manufacturers.2 Between 2012 and 2016, about half 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Most new cancer drugs approved by the European Medicines Agency (EMA) 
have been studied in randomised controlled trials, considered to be the “gold 
standard” for evaluating treatment efficacy
Design characteristics, risk of bias, and reporting of randomised controlled trials 
that support recent EMA cancer drug approvals have not been evaluated
WHAT THIS STUDY ADDS
Around half of randomised controlled trials that supported European cancer drug 
approvals from 2014 to 2016 were assessed to be at high risk of bias based on 
characteristics of their design, conduct, or analysis; trials that evaluated overall 
survival were at lower risk of bias than those that evaluated surrogate measures 
of clinical benefit
Risk of bias judgments differed when using information available from the 
scientific literature and European regulatory documents separately, which 
highlights persistent limitations in information available in regulatory documents 
and published papers
European regulators frequently raised questions about the appropriateness and 
applicability of the available evidence on new cancer drugs, which were not 
acknowledged in the scientific literature
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of new drugs approved by the EMA were associated 
with a single pivotal study.3
Recently, cancer drugs have comprised the single 
largest category of new drug approvals in Europe. In 
2017, more than a quarter (24/92) of EMA approvals 
were for cancer drugs.4 There is considerable debate 
and controversy about the therapeutic and economic 
value of these drugs.5-10 Our recent research showed 
that most new cancer drugs were approved by the 
EMA without evidence of benefit on overall survival 
or quality of life.11 In recent years there has been a 
substantial shift towards use of surrogate endpoints 
such as progression free survival.12 There is growing 
recognition that the correlation between surrogate 
endpoints and overall survival is often poor.13
About a third of “positive” randomised controlled 
trials of cancer drugs report treatment effects that are 
considered to be clinically meaningful according to 
the European Society of Medical Oncology Magnitude 
of Clinical Benefit Scale.5 14 Moreover, there is no 
association between magnitude of benefit and drug 
price.15 Because cancer drugs are responsible for most 
of the recent increases in pharmaceutical spending 
across healthcare systems,16 the evidence base that 
supports their market entry warrants close scrutiny.
Previous work described the characteristics of 
pivotal studies supporting new cancer drug approvals 
in Europe and the United States. Regulators in both 
settings generally review the same set of clinical studies 
when approving new drugs.17 In a large evaluation 
that focused on US Food and Drug Administration 
approvals, clinical studies of cancer drugs were less 
likely to be randomised and double blinded than 
clinical studies of drugs in other therapeutic areas.18 
In another US study, cancer drugs with orphan (rare 
disease) designations were less likely to be randomised 
and double blinded than non-orphan cancer drugs.19 
In Europe, most of the new cancer drug approvals 
between 2009 and 2013 were supported by at least one 
randomised controlled trial.11 However, an increasing 
proportion of new cancer drugs are approved on the 
basis of non-randomised, single arm studies.5
Randomised controlled trials are widely considered 
to be the “gold standard” for evaluating the clinical 
efficacy of new drugs.20 However, flaws in the design, 
conduct, analysis, or reporting of randomised 
controlled trials can produce bias in estimates 
of treatment effect, potentially jeopardising the 
validity of their findings. A large body of literature 
documents these biases, which could be substantial 
in magnitude.21-27 For example, in a large meta-
epidemiological study of 1973 randomised controlled 
trials, lack of blinding was associated with an average 
22% exaggeration of treatment effects among trials 
that reported subjectively assessed outcomes.27 Such 
non-trivial differences could affect how trial results are 
interpreted and used in regulatory settings and clinical 
practice. Therefore, it is imperative to systematically 
examine the validity of randomised controlled trials 
that support the approval of new drugs through 
assessment of the risk of bias in their results.28
In this study, we examined the characteristics of 
randomised controlled trials that supported approval 
of cancer drugs by the EMA from 2014 to 2016. We 
focused on three aspects of cancer drug trials. The first 
aspect was trial design. A key feature of cancer drug 
trials is whether they are designed to demonstrate a 
benefit on overall survival or quality of life.12 29 30 We 
determined whether recent randomised controlled trials 
of cancer drugs included overall survival or quality of 
life outcomes as endpoints. The second aspect was risk 
of bias. Previous studies primarily focused on crude 
metrics of trial quality such as blinding of participants 
and investigators.18 19 31 Although these aspects are 
important, they are not an adequate measure of a trial’s 
validity because randomised controlled trials with 
blinding might still be at high risk of bias (conversely, 
trials without blinding could produce valid results).32 
We aimed to perform risk of bias assessments that more 
thoroughly evaluated deficits in the design, conduct, 
analysis, and reporting of randomised controlled trials.28 
The third aspect was the adequacy, completeness, and 
consistency of reporting across different sources. Trial 
reporting has improved substantially over the past 
few decades.33 Yet, discrepancies can occur between 
regulatory documents and scientific publications,34 and 
might lead to different interpretations. We investigated 
such discrepancies.
Methods
Identification of cancer drug approvals
Two researchers (XRS and NH) independently searched 
the publicly available EMA database of European 
public assessment reports from 1 January 2014 to 31 
December 2016. They used Anatomical Therapeutic 
Chemical Classification (ATC) codes L01-04 to identify 
“antineoplastic and immunomodulating” agents for 
solid tumours and haematological malignancies that 
received “first marketing authorisations”. A third 
researcher (HN) independently confirmed the sample 
of cancer drug approvals during this period. We 
excluded “type 2 variations,” which are additional 
marketing authorisations of already approved drugs in 
new therapeutic indications.
Our study period ended in 2016, which allowed 
a minimum of one year for trials to be published 
in the peer reviewed literature after authorisation. 
We excluded approvals for the treatment of benign 
tumours, supportive treatments, and generic products, 
which was consistent with our previous study.11
We noted when a drug received a “conditional 
marketing authorisation” from the EMA. Conditional 
marketing authorisations are granted for drugs aimed 
at treating serious or life threatening conditions 
with an unmet medical need.35 Such approvals rely 
on less comprehensive data than those required for 
regular marketing authorisations, and pharmaceutical 
companies are required to conduct additional studies 
to evaluate the clinical benefit of their products after 
market entry.36 37 We also noted if a drug received an 
“orphan drug” designation, which is granted for the 
treatment of rare diseases.
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Identification of pivotal trials supporting cancer 
drug approvals
We included the pivotal studies that formed the basis 
of cancer drug approvals during our study period. Two 
researchers (XRS and NH) independently identified the 
pivotal studies, which were defined as those labelled 
as “main studies” in the European public assessment 
reports on the EMA website. A third researcher (HN) 
confirmed the list of pivotal studies. European public 
assessment reports are summaries of documents 
compiled by rapporteurs from European member states 
by using data submitted by pharmaceutical companies. 
These reports include publicly available information 
on the characteristics, findings, and EMA’s appraisal 
of pivotal and supportive clinical studies that support 
marketing authorisation decisions of new products.
Regulatory approval could precede the publication 
of trial results in the scientific literature. We searched 
publicly available clinical trial registries in Europe 
(European Clinical Trials Database: EudraCT) and the 
US (US National Library of Medicine database of clinical 
trials: ClinicalTrials.gov) to identify published accounts 
of pivotal studies in the scientific literature. The latest 
search date was 15 May 2018. ClinicalTrials.gov 
routinely searches PubMed and automatically retrieves 
the peer reviewed publications associated with each 
record in the registry (study sponsors can also manually 
enter information on trial publications in ClinicalTrials.
gov).38 Therefore, we primarily relied on ClinicalTrials.
gov to identify the publications of pivotal studies 
supporting EMA approvals during our study period. We 
cross checked EudraCT to capture any studies which 
might have been missed in ClinicalTrials.gov. If available, 
we also identified the protocols and supplementary 
appendices of pivotal studies. When the protocol was 
not available, we contacted the corresponding authors 
and requested access to their study protocol.
Data collection on study design characteristics
We documented the therapeutic indications for 
which cancer drugs received EMA first marketing 
authorisations. Pivotal studies were then characterised 
in terms of their design (randomised v non-
randomised), study arms (experimental treatment and 
comparators), and primary and secondary endpoints. 
We categorised pivotal studies as randomised 
controlled trials if participants were randomly allocated 
to different treatment arms. We noted if trial endpoints 
included overall survival, health related quality of 
life, progression free survival, disease response rates 
or response duration. In addition to recording the 
primary endpoint of each study, we noted whether 
the secondary endpoints included overall survival 
or quality of life outcomes. All data were collected 
independently by two researchers (XRS and NH) and 
verified by a third (HN).
Risk of bias assessment in randomised trials
We used the revised Cochrane risk of bias assessment 
tool (RoB 2.0, version 2016, available at www.
riskofbias.info) to examine the internal validity of 
randomised controlled trials.39 The Cochrane risk of 
bias tool was initially published in 200828 and has 
been widely used in systematic reviews of randomised 
controlled trials.40 The updated version considers five 
bias domains: (a) bias arising from the randomisation 
process; (b) bias owing to deviations from intended 
interventions; (c) bias caused by missing outcome 
data; (d) bias in measurement of the outcome; and 
(e) bias in selection of the reported result.41 Risk of 
bias judgments were based on answers to a series of 
signalling questions in each of the five bias domains. 
We relied on the tool’s standard algorithms to map 
our responses to signalling questions to risk of 
bias judgments. As recommended in the guidance 
document, if a trial was judged to be at “high risk of 
bias” in one domain, we considered it to be at high 
risk of bias overall.39 In addition, a trial judged to 
have “some concerns” in three or more domains was 
considered to be at high risk of bias overall.39
Our assessment focused on the primary endpoint 
of each pivotal randomised controlled trial. If a trial 
had clinical and surrogate measures as coprimary 
endpoints, we relied on the clinical outcome (for 
example, risk of bias assessment was based on 
overall survival if a trial included overall survival and 
progression free survival as coprimary endpoints), 
unless data were only available for the surrogate 
measure at the time of EMA approval.
On the first domain, trials were judged to be at low 
risk of bias if they adopted appropriate methods to 
generate and conceal the allocation sequence.42 43 We 
also examined whether there were imbalances in group 
sizes, baseline characteristics, or key prognostic factors 
that suggested a problem with the randomisation 
process. Previous meta-epidemiological studies 
have shown that trials with inadequate or unclear 
sequence generation and allocation concealment 
have on average 7-10% exaggerated treatment effects 
compared with trials with adequate methods.26
On the second domain, our assessment was based on 
the effect of assignment to the interventions at baseline 
(the “intention to treat” effect). Studies were at low 
risk of bias if there were no deviations from intended 
interventions. We judged trials to be at high risk of bias 
if there were clear deviations from the intervention that 
was intended in the trial protocol; if such deviations 
were not balanced between the experimental 
and control groups; and if these deviations likely 
influenced the outcome. Trials were also judged to be 
at high risk of bias on this domain if some participants 
were not analysed in the group to which they were 
randomised and if there was potential for a substantial 
impact on study findings. Open label trials were not 
automatically at high risk of bias owing to deviations 
from intended interventions; similarly, trials with 
blinding were not immune to bias by default. In trials 
that masked participants, carers, and trial personnel, 
we carefully considered whether blinding could be 
compromised because of major differences in drug 
adverse events.44  45 However, compromised blinding 
led to high risk of bias judgments for this domain only 
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if there were deviations from intended interventions 
that were not balanced between groups and potentially 
influenced the outcome.
On the third domain, studies were at low risk of 
bias if outcome data were available for all or nearly all 
randomised participants, as reported in the CONSORT 
(Consolidated Standards of Reporting Trials) flow 
diagram.46 Unless there was evidence that results were 
robust to missing outcome data in sensitivity analyses, 
we considered trials to be at high risk of bias if the 
proportions of, or reasons for, missing outcome data 
differed between experimental and control groups 
(potentially resulting in an imbalance in censoring 
rates).47 48 For time to event analyses, trials were judged 
to be at high risk of bias if, firstly, the proportions of 
participants who withdrew their consent to take part in 
the study differed between trial arms, and participants 
were censored when they withdrew consent; or secondly, 
participants who discontinued treatment were censored. 
In these cases, missingness could depend on the true 
value of the outcome. In some trials, patients who 
withdrew their consent continued to be followed up 
and contribute outcome data, unless they specifically 
withdrew their consent for further tumour assessments. 
In such cases, we judged the trials to be at low risk of bias.
On the fourth domain, studies were at low risk of bias 
if outcome assessors were unaware of the intervention 
received by the study participants. We judged trials to 
be at high risk of bias if outcome assessors were not 
masked (or if blinding could be compromised) and 
outcome assessment could be influenced by knowledge 
of the intervention received. According to previous 
meta-epidemiological reviews, lack of blinding of 
outcome assessors in randomised controlled trials is 
associated with 36% exaggerated treatment effects for 
subjective outcomes.49
On the fifth domain, studies were at low risk of bias 
if the results were unlikely to have been selected on 
the basis of either multiple outcome measurements or 
multiple analyses of the data.
Two trained researchers (XRS and NH) independently 
assessed the risk of bias in each pivotal randomised 
controlled trial. Areas of disagreement were resolved 
by discussion and consensus in face to face meetings, 
first between the two researchers and then with 
other members of the project team (HN and CD). Two 
researchers reached the same overall risk of bias 
judgment for 74% of trials when using the published 
articles and for 85% of trials when using the European 
regulatory documents. A third researcher (HN) 
independently reviewed and confirmed the accuracy 
of all assessments. Difficult cases were also discussed 
among team members with methodological (JS, JPTH, 
and JACS) and clinical (BG) expertise.
Reporting adequacy in regulatory documents and 
scientific literature
We assessed the risk of bias in each randomised controlled 
trial twice to compare the completeness and consistency of 
trial reporting in the regulatory documents and scientific 
literature.50 Firstly, we relied on the published articles, 
and if available, their protocols and supplementary 
appendices. Secondly, we repeated the assessments 
by using information available in European public 
assessment reports alone (without consulting the trial 
publication, its protocol and supplementary appendix, or 
clinical trial registry records). There was a minimum “wash 
out” period of four weeks between assessments. If our risk 
of bias judgment differed when we used information from 
regulatory documents versus publications, we noted the 
reasons for the observed discrepancies. A third version of 
each risk of bias assessment was derived using the totality 
of information available for each trial by combining the 
scientific literature and regulatory documents (“combined 
information”).
Finally, one researcher (HN) documented the 
additional limitations of the available evidence 
highlighted in European public assessment reports and 
whether these were acknowledged in trial publications. 
These issues were related to the appropriateness and 
generalisability of the available evidence and focused 
on trial features that were not included in the five 
domains of the Cochrane risk of bias tool. For example, 
regulators often commented on the magnitude of 
clinical benefit, choice of comparators, and endpoints 
because these could affect the relevance of trial 
findings to clinical practice. Similarly, “maturity” of 
statistical analyses was routinely discussed because 
early termination of trials could affect the reliability 
and interpretation of findings, especially when interim 
analyses are not prespecified.51 52
Patient and public involvement
No patients or members of the public were involved in 
setting the research question or the outcome measures, 
nor were they involved in developing plans for design 
or implementation of the study. No patients or members 
of the public were asked to advise on interpretation 
or writing up of results. We plan to involve patients 
and members of the public when disseminating the 
study results on a publicly available website. We plan 
to disseminate the findings of this work to patient 
organisations.
Results
Cancer drug approvals
Figure 1 shows the process that led to identification of 
our study sample. Of 64 potentially relevant marketing 
authorisations granted by the EMA between 1 January 
2014 and 31 December 2016, 48 were for cancer 
products. After we excluded 16 generic and supportive 
care drugs, our sample consisted of 32 cancer drug 
approvals. A total of five (16%) approvals were 
indicated for the treatment of multiple myeloma, four 
(13%) for melanoma, and four (13%) for lung cancer 
(appendix table 1). During this period, 13 (41%) cancer 
drugs were approved for orphan indications and five 
(16%) received conditional marketing authorisations.
Characteristics of pivotal trials
Thirty two cancer drug approvals were supported by 54 
pivotal studies. Of these, 41 (76%) were randomised 
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controlled trials (two of which randomised patients 
to different doses of the experimental treatment), 
11 (20%) were single arm studies that evaluated the 
experimental treatment alone without a comparator, 
and 2 (4%) were non-randomised comparative studies. 
Only seven cancer drug approvals were supported by 
two or more randomised controlled trials. Two of 13 
cancer drugs (15%) with orphan designation were 
supported by single arm studies alone compared with 
2 of 19 non-orphan drugs (11%). Two of 5 cancer drugs 
(40%) with conditional marketing authorisations were 
supported by single arm studies alone, whereas 2 of 
27 drugs (7%) with regular approvals had only single 
arm studies.
We were able to identify published accounts of 39 of 
41 randomised controlled trials. The two unpublished 
randomised controlled trials were for pegaspargase, 
which was previously approved by national health 
authorities in several European countries. European 
public assessment reports were available for all 39 
randomised controlled trials. Trial protocols were 
publicly available for 21 randomised controlled trials 
and we gained access to two additional protocols.
Only 10 of 39 randomised controlled trials (26%) 
evaluated overall survival as either a primary or 
coprimary endpoint (appendix table 2). Progression 
free survival was the primary endpoint in 21 
randomised controlled trials (54%), whereas the 
remaining trials evaluated disease response, event free 
survival, or safety endpoints.
Risk of bias
Figure 2 shows the risk of bias in pivotal randomised 
controlled trials of cancer drugs by using combined 
information obtained from regulatory documents 
and the scientific literature. Based on our answers to 
signalling questions (appendix table 3), we judged 
two trials to be at high risk of bias that arose from the 
randomisation process. Four trials were at high risk of 
bias owing to deviations from intended interventions. 
Twenty three randomised controlled trials had 
some concerns because of deviations from intended 
interventions, which reflected either lack of blinding 
or risk of compromised blinding; however, none of 
these was responsible for a high risk of bias judgment 
overall. Ten trials were judged to be at high risk of bias 
owing to missing outcome data and seven because 
of measurement of the outcome. All randomised 
controlled trials were at low risk of bias in selection of 
the reported result.
Taken together, 19 randomised controlled trials 
(49%) were at high risk of bias overall, 2 (5%) had 
some concerns, and 18 (46%) were at low risk of 
bias according to our assessments using the revised 
Cochrane tool. Of the 19 randomised controlled trials 
that were at high risk of bias overall, 13 had one 
domain at high risk of bias, 5 had two domains at 
high risk of bias, and 1 had three domains with some 
concerns. Detailed justifications for our judgments are 
included in appendix table 3.
Fewer randomised controlled trials that evaluated 
overall survival as the primary or coprimary endpoint 
were at high risk of bias than those that evaluated 
surrogate efficacy endpoints (2/10 (20%) v 16/29 
(55%), respectively). Of the 16 randomised controlled 
trials with surrogate endpoints that were at high risk of 
bias, our judgments were informed by concerns about 
missing outcome data for six randomised controlled 
trials; measurement of the outcome for three randomised 
controlled trials; and a combination of domains for 
seven randomised controlled trials.
Reporting adequacy
Figure 3 shows the domain specific risk of bias 
judgments when we considered information reported 
in the scientific literature (trial publication, protocol, 
appendix, clinical trial registry record) and European 
public assessment reports separately. Our judgments 
differed for at least one domain in 26 out of 39 
randomised controlled trials (table 1). Most of these 
differences did not change the overall risk of bias 
judgments, however our conclusions changed for eight 
randomised controlled trials (21%).
Table 1 lists the reasons for observed differences. 
Overall, the content and consistency of reporting 
varied between the two sources. For example, the 
methods adopted in generating and concealing the 
allocation sequence were more readily available in 
the scientific literature than in regulatory documents 
(n=15). In contrast, major protocol deviations were 
only explicitly reported in regulatory documents, 
albeit inconsistently (n=3). Although protocols were 
available for 23/39 randomised controlled trials 
in our sample, we could not spot major deviations 
without explicit acknowledgment and discussion of 
such deviations in the reports. For the remaining bias 
domains, there was no discernible pattern. While some 
regulatory documents had more complete reporting in 
terms of missing outcome data, this information was 
Total number of drug approvals identified (L01-04)
Excluded
Generic cancer drug approvals
Supportive care
13
3
Randomised41* Non-randomised2 Single arm11
Not cancer drug
Cancer related drug approvals
Cancer drug approvals
Supported by 54 pivotal trials
64
48
16
32
16
Fig 1 | Identification and selection of cancer drug approvals. *One randomised study 
corresponds to four separate publications submitted to the European Medicines Agency 
as bibliographic references. This study was not evaluated further. L01-04=Anatomical 
Therapeutic Chemical Classification (ATC) codes 
 o
n
 4 O
ctober 2019 at University of Bristol Library. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l5221 on 18 September 2019. Downloaded from 
RESEARCH
6 doi: 10.1136/bmj.l5221 | BMJ 2019;366:l5221 | the bmj
Drug name (generic) Name of study
Primary
efficacy
endpoint 
Ra
nd
om
is
at
io
n
D
ev
ia
tio
ns
fr
om
 in
te
nd
ed
in
te
rv
en
tio
ns
M
is
si
ng
ou
tc
om
e
da
ta
 
M
ea
su
re
m
en
t
of
 th
e 
ou
tc
om
e 
Se
le
ct
io
n 
of
re
po
rt
ed
 re
su
lt 
O
ve
ra
ll 
ris
k 
of
 b
ia
s
Cabozantinib XL184 -301 PFS
Trametinib MEK114267 PFS
Trametinib BRF113220 Response, PFS
Trametinib MEK115306 PFS
Obinutuzumab BO21004/CLL11 PFS
Idelalisib GS -US-312-0116 PFS
Ibrutinib Study 1112 PFS
Nintedanib LUME Lung 1–1199.13 PFS
Olaparib D0810C00019 PFS
Ramucirumab I4T-IE-JVBD(REGARD) OS
Ramucirumab I4T-IE-JVBE(RAINBOW) OS
Lenvatinib E7080-G000-303(SELECT) PFS
Nivolumab CA209-066 OS
Nivolumab CA209-037 Response, OS
Pembrolizumab Study P002 PFS, OS
Pembrolizumab Study P006 PFS, OS
Sonidegib CLDE225A2201 (BOLT) Response
Panobinostat CLBH589D2308 (Panorama I) PFS
Carfilzomib PX-171-009(ASPIRE Study) PFS
Cobimetinib GO28141 (coBRIM) PFS
Talimogene laherparepvec Study 005/05 Response
Pegaspargase CCG-1962 No efficacy
Pegaspargase DFCI-87-001 EFS
Pegaspargase DFCI-91-01 EFS
Pegaspargase DFCI-05-001 DFS, OS, HRQoL
Pegaspargase AALL07P4 No efficacy
Pegaspargase ASP-304 Response
Necitumumab I4X-IE-JFCC(SQUIRE) OS
Trifluridine/tipiracil TPU-TAS-102-301(RECOURSE) OS
Elotuzumab CA204-004 PFS, Response
Elotuzumab CA204-009 PFS
Daratumumab MMY2002 Response
Lenvatinib E7080-G000-205 PFS
Cabozantinib XL184-308 PFS
Irinotecan hydrochloride 
trihydrate NAPOLI-1 OS
Olaratumab I5B-IE-JGDG(JGDG) PFS
Palbociclib 1023 (PALOMA-3) PFS
Palbociclib 1008 (PALOMA-2) PFS
Ixazomib C16010 PFS
LowSome concernsHigh
Fig 2 | Risk of bias assessment for the pivotal randomised controlled trials supporting European Medicines 
Agency cancer drug approvals using information available in the scientific literature (trial publications, protocols, 
supplementary materials, and clinical trial registry records) and regulatory documents. Risk of bias assessments were 
based on the primary efficacy endpoints. DFS=disease free survival; EFS=event free survival; HRQoL=health related 
quality of life; OS=overall survival; PFS=progression free survival
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more routinely and comprehensively reported in the 
scientific literature in other cases.
Regulatory reviewers identified additional limitations 
in the evidence base beyond the domains captured 
in the risk of bias assessments for 10 drugs (32%). 
These limitations focused on the appropriateness and 
generalisability of the available data and included 
choice of comparators, study endpoints, interim 
analyses, or a combination of factors (box 1). In five 
cases, the committee questioned either the consistency 
or magnitude of the observed clinical benefit. The 
regulatory reviewers raised concerns that were 
substantial enough to warrant a divergent committee 
opinion in four cases, all of which were judged to be at 
low risk of bias according to our risk of bias assessment. 
None of these regulatory concerns were fully disclosed 
and discussed as limitations or uncertainties in the 
scientific literature (appendix box 1).
Results summary
Table 2 summarises our findings at the cancer drug 
level. Of 32 new cancer drugs approved by the EMA 
from 2014 to 2016, 27 entered the European market 
with at least one randomised trial. Of the cancer drugs 
with randomised controlled trials, only seven were 
evaluated in trials powered to measure overall survival 
as a primary or coprimary endpoint. Half (n=16) of 
cancer drugs had at least one randomised controlled 
trial at low risk of bias. European regulators identified 
other concerns for 7 of the 16 drugs that had at least 
one randomised controlled trial at low risk of bias.
Figure 4 summarises our findings according to 
approval characteristics. Of 13 cancer drugs approved 
in orphan conditions, 4 (31%) had at least one 
randomised controlled trial at low risk of bias and 
without major regulatory concerns. The corresponding 
number was 5 among the subset of 19 drugs (26%) 
approved in non-orphan conditions. A lower 
proportion of cancer drugs with conditional marketing 
authorisations had at least one randomised controlled 
trial at low risk of bias and without major regulatory 
concerns compared with drugs with regular EMA 
approvals (1/5 (20%) v 8/27 (30%), respectively).
Discussion
Summary of findings
In this study, we evaluated the evidence base 
underpinning the EMA’s recent cancer drug 
approvals. Between 2014 and 2016, a quarter of 
pivotal studies supporting cancer drug approvals 
were not randomised designs. Of the 39 randomised 
controlled trials that formed the basis of new cancer 
drug approvals, almost three quarters did not measure 
overall survival or quality of life outcomes as primary 
endpoints. Using the revised Cochrane tool, we judged 
49% of randomised controlled trials to be at high risk 
of bias. Our judgments changed in either direction for 
a fifth of randomised controlled trials when we relied 
on information reported in regulatory documents and 
scientific publications separately. Regulators identified 
additional deficits beyond the domains captured in 
risk of bias assessments for several trials, which were 
not disclosed as limitations in scientific publications.
The three key findings of this study warrant further 
discussion. Firstly, our evaluation characterises the 
design features of contemporary cancer drug trials. 
Although randomised controlled trials accounted for 
about 90% of pivotal studies from 2009 to 2013,11 
such designs accounted for 75% of studies from 2014 
to 2016. A growing proportion of recent cancer drug 
approvals were based on single arm studies, which 
are more likely to receive conditional marketing 
authorisations that target indications with unmet 
medical need.53 Even when trials had comparators, 
their appropriateness was at times questionable. 
Scientific literature and regulatory documents
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Fig 3 | Risk of bias assessments using combined information from the scientific 
literature and regulatory documents, only information available in the scientific 
literature, and only information available in regulatory documents. Risk of bias 
assessments were based on the primary efficacy endpoints
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Table 1 | Reasons for differences in risk of bias judgments according to scientific literature and regulatory documents (only randomised controlled trials 
with different risk of bias judgments are listed)
Drug name (generic) Name of study Observed discrepancy Reason for discrepancy
Cabozantinib XL184-301 Deviation from intended interventions: some concerns in published reports and high risk of bias in EPAR EPAR provided additional detail on major protocol deviations
Trametinib BRF113220
Randomisation: low risk of bias in published reports and high 
risk of bias in EPAR. Missing outcome data: some concerns in 
published reports and high risk of bias in EPAR
EPAR lacked information on randomisation methods. EPAR 
provided additional detail on (non-event related) censoring 
of participants
Trametinib MEK115306
Randomisation: low risk of bias in published reports and high 
risk of bias in EPAR. Missing outcome data: low risk of bias in 
published reports and high risk of bias in EPAR
EPAR lacked information on randomisation methods. EPAR 
provided additional detail on the number of participants 
with censoring
Idelalisib GS-US-312-0116 Missing outcome data: low risk of bias in published reports and high risk of bias in EPAR
Numbers of participants who withdrew their consent do not 
match between the participant disposition reported in EPAR 
and supplementary appendix of publication
Ibrutinib Study 1112 Randomisation: low risk of bias in published reports and some concerns in EPAR EPAR lacked information on randomisation methods
Nintedanib LUME Lung 1 – 1199.13 Randomisation: low risk of bias in published reports and some concerns in EPAR EPAR lacked information on randomisation methods
Olaparib D0810C00019 Randomisation: low risk of bias in published reports and some concerns in EPAR EPAR lacked information on randomisation methods
Ramucirumab I4T-IE-JVBD (REGARD) Randomisation: low risk of bias in published reports and some concerns in EPAR EPAR lacked information on randomisation methods
Sonidegib CLDE225A2201 (BOLT) Randomisation: low risk of bias in published reports and some concerns in EPAR EPAR lacked information on randomisation methods
Panobinostat CLBH589D2308  (Panorama I)
Missing outcome data: low risk of bias in published reports and 
high risk of bias in EPAR
Supplementary appendix of published report included 
 results from sensitivity analyses that tested different 
 censoring rules. EPAR did not report these results
Carfilzomib PX-171-009  (ASPIRE Study)
Deviation from intervention intended interventions: some 
concerns in published reports and high risk of bias in EPAR
EPAR reported the proportion of participants with major 
protocol deviations, which differed across trial arms
Talimogene 
 laherparepvec Study 005/05
Missing outcome data: high risk of bias in published reports 
and low risk of bias in EPAR. Measurement of the outcome: low 
risk of bias in published reports and some concerns in EPAR
EPAR reported findings of sensitivity analyses that tested 
different censoring rules (not available in publication). EPAR 
provided additional information on outcome assessment
Pegaspargase CCG-1962 Missing outcome data: some concerns in published report and low risk of bias in EPAR
EPAR provided more information about study and treatment 
discontinuations
Pegaspargase DFCI-87-001
Randomisation: low risk of bias in publication and some 
concerns in EPAR. Missing outcome data: low risk of bias in 
published report and high risk of bias in EPAR
EPAR lacked information on randomisation methods. 
 Number of randomised and assessed participants did not 
match between publication and EPAR
Pegaspargase DFCI-91-01 Randomisation: low risk of bias in publication and some concerns in EPAR EPAR lacked information on randomisation methods
Pegaspargase DFCI-05-001
Randomisation: low risk of bias in published report and some 
concerns in EPAR. Missing outcome data: low risk of bias in 
publication and some concerns in EPAR
Published report provided additional information about 
availability of outcome data
Pegaspargase AALL07P4 Missing outcome data: high risk of bias in published report and some concerns in EPAR
Published report provided additional information about 
availability of outcome data
Pegaspargase ASP-304 Missing outcome data: some concerns in published report and low risk of bias EPAR
EPAR provided more detailed information about outcome 
data availability
Elotuzumab CA204-009
Randomisation: some concerns in published reports and low 
risk of bias in EPAR. Deviation from intended intervention: 
some concerns in publication and low risk of bias in EPAR. 
Missing outcome data: low risk of bias in published reports and 
high risk of bias in EPAR
EPAR provided slightly more information on randomisation 
methods. EPAR reported that major protocol deviations were 
balanced between trial arms. Findings of sensitivity analyses 
that tested different censoring rules were available only in 
published reports
Daratumumab MMY2002 Randomisation: low risk of bias in published reports and high risk of bias in EPAR
EPAR provided more detail on different parts of the trial, 
which were not randomised
Lenvatinib E7080-G000-205
Deviation from intended intervention: some concerns in 
published report and low risk of bias in EPAR. Missing outcome 
data: high risk of bias in published report and low risk of bias 
in EPAR. Measurement of the outcome: high risk of bias in 
published report and low risk of bias in EPAR
EPAR reported that protocol deviations were balanced 
across trial arms. EPAR also reported the findings of 
 sensitivity  analyses testing different censoring rules. Results 
of  outcome assessment by an independent panel were 
reported in EPAR
Cabozantinib XL184-308
Randomisation: low risk of bias in published report and some 
concerns in EPAR. Deviation from intended intervention: some 
concerns in published report and low risk of bias in EPAR
EPAR lacked information on randomisation methods. 
EPAR provided information on protocol deviations, which 
appeared balanced across trial arms
Olaratumab I5B-IE-JGDG (JGDG) Missing outcome data: high risk of bias in published report and low risk of bias in EPAR
EPAR reported findings from sensitivity analyses that tested 
different censoring rules
Palbociclib 1023 (PALOMA-3) Randomisation: low risk of bias in published report and some concerns in EPAR EPAR lacked information on randomisation methods
Palbociclib 1008 (PALOMA-2)
Randomisation: low risk of bias in published report and some 
concerns in EPAR. Deviation from intended intervention: some 
concerns in published report and high risk of bias in EPAR
EPAR lacked information on randomisation methods. EPAR 
reported major protocol deviations, which differed across 
trial arms
Ixazomib C16010 Randomisation: low risk of bias in published report and some concerns in EPAR EPAR lacked information on randomisation methods
EPAR=European public assessment report.
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Box 1: Major concerns raised in European regulatory documents (appendix box 1 includes a more detailed 
narrative overview of these cases) 
Idelalisib: early termination of trial
• The pivotal study was terminated early owing to efficacy. According to the EPAR, “the magnitude of the treatment 
effect is therefore not well defined and further follow-up is needed.”
• This need was acknowledged in the published article for safety evaluation but not to confirm clinical benefit.
Olaparib: non-preferred outcome; retrospective subgroup analysis
• Regulators had previously advised the manufacturer to evaluate overall survival as the trial’s primary endpoint; 
however, this recommendation was not followed.
• The target patient population for which approval was sought was retrospectively defined. In addition, “the SAG was 
uncertain about the true effect of olaparib in this [target] patient population due to the shortcomings of the pivotal 
study being a small phase II randomised study with a large percentage of censored observations for PFS analysis, and 
in view of the absence of improvement in OS.”
• These limitations were not acknowledged in the published article. However, the published article reported that: “Our 
data cannot address differences that might exist between patients with BRCA germline mutations and those with a 
BRCAness phenotype.”
Ramucirumab: inconsistent effects across settings and demographic characteristics; divergent committee opinion
• According to the EPAR, there was a differential OS outcome across regions in the REGARD study. “Inconsistency was 
also observed regarding gender (ramucirumab effective in men, but potentially detrimental in women).”
• In addition, some CHMP members “considered that the effect associated with ramucirumab as single agent was too 
marginal and possibly even inferior to single agent chemotherapy that are used in this setting.”
• In contrast, the published article for the REGARD study stated that: “the survival benefit with ramucirumab was 
consistent across almost all subgroups. Although the effect on OS was attenuated in women, the PFS estimate in 
women favoured ramucirumab.”
Nivolumab: unplanned early termination of trial due to observed efficacy; non-preferred outcome; potential imbalances in 
baseline characteristics
• According to the EPAR, “the CHMP was concerned that … carrying out an unplanned interim analysis … was 
questionable and would introduce uncertainties such as the potential for informative bias.” While the published 
article specified that this analysis was “unplanned,” it did not comment on the potential implications of this decision.
• The CHMP highlighted that use of ORR as a primary endpoint in study CA209-037 was not recommended and “OS 
should have been favoured as primary endpoint …”
• In addition, “the CHMP had concerns over the shape of the OS curves … The applicant provided a discussion on 
the possible confounding factors, mainly that there were baseline imbalances between the nivolumab arm and 
chemotherapy arm.”
• Although the published article reported that “baseline characteristics were similar in the nivolumab and 
[investigators’ choice chemotherapy] study groups, with the exception of history of brain metastases and high lactase 
dehydrogenase, which were higher in the nivolumab than the [investigators’ choice chemotherapy group],” findings 
on OS were not reported.
Panobinostat: questionable clinical benefit
• According to the EPAR, the CHMP concluded that “the benefit in PFS has not been translated into a similar relative 
benefit in OS.” A SAG meeting was convened to discuss whether the clinical benefit of panobinostat was “sufficient to 
justify exposing these patients to the severe adverse event profile of the drug.”
• Some members of the SAG concluded that “the clinical benefit cannot be considered established.” Such concerns 
were not disclosed or discussed in the published article.
• While the EPAR showed that “the results from the EORTC QLQ-C30 captured a consistently negative effect by the 
experimental regimen compared to the control arm …,” these results were not reported in the primary publication of 
the trial.
Cobimetinib: appropriateness of comparator arms
• According to the EPAR, “the CHMP expressed some concern over the lack of a cobimetinib only treatment arm.”
• Appropriateness of the comparator arm was not discussed in the published article.
Talimogene: appropriateness of comparator arms; questionable clinical benefit; questionable study endpoints; divergent 
committee opinion
• According to the EPAR, there were several concerns with the pivotal study supporting this approval.
• The CAT expressed concerns over the comparator; questioned “the validity of using DRR as the primary endpoint for 
the pivotal trials as opposed to using other more robust endpoints such as PFS or OS”; and questioned the clinical 
relevance of the magnitude of treatment effect on DRR.
• In addition, “although there appeared to be an effect on OS in the subgroup of patients with Stage IIIB-IVM1a disease, 
OS was a secondary endpoint and the effect was based on exploratory subgroup analyses, after the analysis in the full 
analysis set was not statistically significant, and without a pre-specified strategy for multiplicity adjustment.”
• These concerns led to a divergent opinion on the approval decision.
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We found two randomised controlled trials in which 
participants were randomised to receive different 
doses of the same experimental treatment (without 
a control). In other cases, the comparator either 
precluded isolation of the effect of the experimental 
treatment or did not adequately reflect standard of 
care; these trials were subsequently criticised by the 
EMA. In terms of study endpoints, only a quarter of 
randomised controlled trials were powered to evaluate 
overall survival as the primary outcome. According 
to the recent EMA guidelines on the evaluation of 
anticancer treatments,54 “convincingly demonstrated 
favourable effects on overall survival are from both 
a clinical and methodological perspective the most 
persuasive outcome of a clinical trial.” Yet, most cancer 
drugs were approved on the basis of other endpoints, 
such as progression free survival and disease response. 
Recent systematic reviews showed that progression 
free survival and disease response do not consistently 
translate to survival gains or quality of life benefits.13 55-58 
Cancer drugs that appear effective on these surrogate 
measures could even turn out to be harmful.59
Secondly, the evidence base underpinning EMA 
approvals of new cancer drugs has methodological 
weaknesses. In this study, the primary domains 
responsible for the high risk of bias judgments were 
missing outcome data and measurement of the 
outcome (see box 2 for illustrative examples). In 
several trials, the proportions and reasons for missing 
outcome data differed, which probably resulted in 
unbalanced censoring60 and potentially favoured 
the experimental drug.61 Considerable differences 
in the toxicity profiles of drugs was another common 
issue. When such differences were substantial, we 
concluded that blinding of participants, carers, or 
investigators could be compromised. As recognised by 
EMA scientists, “the real effectiveness of the blinding 
for cancer drugs can always be questioned.”62 We 
judged trials to be at high risk of bias if a subjective 
primary outcome (such as progression free survival) 
was assessed by local investigators who we concluded 
might no longer be blinded to treatment allocation. 
This judgment was also supported by the recent 
US Food and Drug Administration guidelines that 
recommend independent verification of tumour 
assessment endpoints when the adverse event profiles 
of comparator treatments could substantially unblind 
the trial in practice.63
Thirdly, the regulatory documents and scientific 
publications had limitations in their reporting. Some 
Box 1: Continued
• Despite the statement in the EPAR that “it cannot be concluded that an effect on OS has been established for 
talimogene,” the published article reported that it was “well tolerated and resulted in a higher DRR (P<.001) and 
longer median OS (P=.051) …” The discussion section added, “combined with the limited toxicity observed, these are 
clinically important results.”
Necitumumab: questionable clinical benefit; divergent committee opinion
• The magnitude of clinical benefit was questioned by the CHMP, which led to a divergent opinion on the approval 
decision.
• In contrast, the study publication reported that “the addition of a targeted agent to a platinum-based doublet 
improves survival. These efficacy data and the acceptable safety profile of necitumumab suggest a favourable benefit-
to-risk ratio for this combination treatment.”
Daratumumab: appropriateness of comparator arms
• According to the EPAR, “the design of the study with no comparative arm is of concern …”
• This was not highlighted in the published account of the trial. Instead, the publication reported: “although this study 
did not have a control arm, patients with the degree of treatment refractoriness in our study historically have poor 
outcomes.”
Ixazomib: problematic interim analyses; questionable clinical benefit; divergent committee opinion
• The EMA initially refused granting a marketing authorisation to ixazomib, but this decision was subsequently 
overturned. Ultimately, ixazomib received a conditional marketing authorisation.
• There were several concerns regarding the single pivotal trial submitted by the manufacturer. Notably, there was a 
“worsening of results between the initially submitted analysis and the updated analysis.”
• The CHMP therefore concluded that ixazomib “was not approvable based on the efficacy grounds ...”
• In response to the manufacturer’s request for reexamination, a SAG meeting was convened. The SAG “considered 
that on the basis of the primary PFS analysis, which was conducted according to the pre-specified statistical 
considerations, the trial met its objective of showing a statistically and clinically significant improvement in PFS.” 
Although the CHMP still maintained that “the total available evidence on efficacy is not as comprehensive as normally 
would be required,” a conditional marketing authorisation was ultimately granted.
• There was a divergent opinion on the approval decision (signed by nine members of the CHMP).
• The published article only reported the first set of interim results, which were initially submitted to the EMA and stated 
that “in accordance with the statistical analysis plan in the protocol and the principle of group sequential design, this 
was the final statistical analysis of progression free survival” despite providing more mature data on progression free 
survival data to the European regulators.
BRCA=breast cancer gene; CAT=Committee for Advanced Therapies; CHMP=Committee for Medicinal Products for Human Use; DRR=durable disease 
response; EMA=European Medicines Agency; EORTC= European Organisation for Research and Treatment of Cancer; EPAR=European public assessment 
report; ORR=overall response rate; OS=overall survival; PFS=progression free survival; SAG=Scientific Advisory Group.  o
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of these limitations followed a discernible pattern. 
For example, key design elements of randomised 
controlled trials such as sequence generation and 
allocation concealment were consistently reported 
in trial publications, their protocols, or appendices. 
In contrast, regulatory documents seldom specified 
randomisation methods; instead, regulators 
often discussed potential imbalances in baseline 
characteristics to gauge the success of randomisation.64 
Other discrepancies among regulatory documents and 
publications were less predictable. While both sources 
typically showed the flow of participants, strategies 
to deal with missing outcome data and the sensitivity 
of findings to censoring rules and assumptions were 
only haphazardly reported. Moreover, neither source 
consistently reported major deviations from intended 
interventions.
Comparison to other studies in the literature
Previous studies have documented the shift in cancer 
trials away from evaluating overall survival in the 1970s 
to measuring surrogates of clinical benefit in more 
recent decades.29 65 66 Our findings confirm that this 
trend has continued for trials that informed regulatory 
Table 2 | Overview of findings at the drug level. For each cancer drug approval from 2014 to 2016, the table shows whether there was at least one 
randomised controlled trial supporting the EMA’s approval decision; whether there was at least one randomised controlled trial evaluating overall 
survival as a primary or coprimary endpoint; whether there was at least one randomised controlled trial at low risk of bias; whether EMA scientists and 
committee members raised additional concerns about the appropriateness of the available evidence according to factors that were not captured in risk 
of bias assessments; and whether EMA committee members issued a divergent opinion on the approval decision based on those concerns
Drug name (generic) Approval characteristics
Has at least one RCT 
supporting EMA 
approval
Has at least one RCT 
 evaluating OS for 
EMA approval
Has at least one  
RCT at low risk  
of bias
Other regulatory 
concerns raised  
prior to approval
Divergent  regulatory 
opinion on the 
approval
Cabozantinib Orphan; conditional Yes No No No No
Trametinib — Yes No No No No
Obinutuzumab Orphan Yes No Yes No No
Idelalisib — Yes No No Yes No
Ibrutinib Orphan Yes No No No No
Nintedanib — Yes No No No No
Olaparib Orphan Yes No Yes Yes No
Ramucirumab — Yes Yes Yes Yes Yes
Ceritinib — No NA NA NA NA
Lenvatinib Orphan Yes No Yes No No
Nivolumab — Yes Yes Yes Yes No
Pembrolizumab — Yes Yes Yes No No
Sonidegib — Yes No No No No
Panobinostat Orphan Yes No Yes Yes No
Carfilzomib Orphan Yes No No No No
Cobimetinib — Yes No Yes Yes No
Blinatumomab Orphan; conditional No NA NA NA NA
Talimogene — Yes No No Yes Yes
Asparaginase — No NA NA NA NA
Pegaspargase — Yes Yes No No No
Osimertinib — No NA NA NA NA
Necitumumab — Yes Yes Yes Yes Yes
Trifluridine/tipiracil — Yes Yes Yes No No
Elotuzumab — Yes No Yes No No
Daratumumab Orphan Yes No No Yes No
Lenvatinib — Yes No Yes No No
Cabozantinib — Yes No Yes No No
Irinotecan Orphan Yes Yes Yes No No
Olaratumab Orphan; conditional Yes No Yes No No
Palbociclib — Yes No No No No
Ixazomib Orphan; conditional Yes No Yes Yes Yes
Venetoclax Orphan; conditional No NA NA NA NA
EMA=European Medicines Agency; NA=not applicable; OS=overall survival; RCT=randomised controlled trial.
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Fig 4 | Overview of findings at the drug level according to approval characteristics 
(orphan v non-orphan conditions; conditional marketing authorisations v regular 
approvals). The figure shows whether there was at least one randomised controlled trial 
at low risk of bias; and whether there was at least one randomised controlled trial at 
low risk of bias and without major regulatory concerns before approval
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decisions from 2014 to 2016. Similar to recent 
evaluations, we found low risk of bias arising from the 
randomisation process and selection of the reported 
result.33 67 Our concerns about missing outcome data 
were supported by an earlier study which showed that 
about one third of breast cancer trials had differential 
rates and reasons for censoring.61 Finally, our findings 
concur with those from previous studies which showed 
that incorporating data from additional documents 
often improves risk of bias assessments.68-71
Implications for practice and policy
Our findings highlight the need to improve the design, 
conduct, analysis, and reporting of cancer drug trials.72 
Regulatory agencies and their evidence requirements 
shape the design features of pivotal trials.73-75 
Therefore, regulatory action is needed to ensure that 
pharmaceutical manufacturers routinely evaluate 
their products in randomised trials that collect data 
on meaningful outcomes. In the absence of such data, 
it remains difficult to know whether new cancer drugs 
meet the needs of patients, clinicians, and healthcare 
systems.
While some of the methodological problems 
identified in our study were avoidable (for example, by 
ensuring adequate sequence generation and allocation 
concealment), others could be less straightforward 
to address in complex cancer trials. For example, 
ensuring outcome data availability when participants 
withdraw their consent might not be possible. The 
proportions of participants who withdrew their consent 
frequently differed among trial arms, which likely 
reflected meaningful differences in toxicity profiles of 
comparator drugs. In such instances when missingness 
could depend on the true value of the outcome, it is 
essential to evaluate the sensitivity of trial findings to 
different assumptions about missing outcome data.76 
However, some trials censored participants when they 
changed from their assigned treatment. This analysis 
strategy is not appropriate when estimating intention 
to treat effects and could lead to bias because of 
missing outcome data.
Addressing other methodological problems in 
cancer trials could be feasible, but they come at a 
cost. Strategies to prevent unblinding might add 
complexity to trial designs.23 77 For example, methods 
to avoid unblinding in randomised controlled 
trials include centralised dosage modification of 
treatments and centralised assessment of clinical 
side effects.77 Similarly, independent clinicians 
could perform blinded central evaluation of tumour 
assessment endpoints, but this might have major 
cost implications.78 In a recent review of randomised 
controlled trials in solid tumours, there was no 
systematic bias between the findings from blinded 
independent central review and local assessment, 
but there were statistical inconsistencies between 
the two sets of results in almost a quarter of trials.79 
Moreover, previous meta-epidemiological reviews 
across different therapeutic areas have found that 
studies with non-blinded assessors of subjective 
outcomes generate biased findings.49 80 This research 
strengthens the argument in favour of implementing 
blinded centralised assessments of tumour endpoints 
despite the associated costs.
An important design consideration in cancer trials 
is the choice of primary endpoint. Surrogate measures 
of clinical benefit (eg, progression free survival 
and disease response) have important feasibility 
advantages because they can be assessed earlier 
and with smaller sample sizes (and therefore fewer 
resources) compared with overall survival. A recent 
study found that cancer drugs approved on the basis 
of surrogate measures had on average an 11 month 
shorter development duration compared with drugs 
approved on the basis of overall survival.81 However, 
the feasibility advantages of using surrogate measures 
Box 2: Illustrative examples of trials judged to be at high risk of bias because of 
missing outcome data and measurement of the outcome
Elotuzumab
We judged one of the pivotal trials of elotuzumab to be at high risk of bias. In trial CA204-
009, which was open label, outcome assessors were aware of the intervention received 
by study participants, and assessment of the progression free survival outcome could 
have been influenced by knowledge of the intervention received. Because there was no 
blinded central assessment of outcomes, we concluded that this trial was at high risk of 
bias in measurement of the outcome. This potential limitation was also acknowledged 
in the trial publication.
Nivolumab
We judged one of the pivotal trials of nivolumab to be at high risk of bias because 
of missing outcome data. In trial CA209-037, outcome data were potentially 
missing for a considerable proportion of the population. In the investigator’s choice 
chemotherapy arm of the trial, 22/133 (16.5%) patients withdrew their consent, which 
meant withdrawing consent from the full protocol, including study treatment, study 
procedures, and survival follow-up. Proportions of missing outcome data and reasons 
for missing outcome data differed across intervention groups: 16.5% v <1% of patients 
withdrew their consent in the investigator’s choice chemotherapy and nivolumab 
arms of the trial, respectively. Missingness in the outcome could be related to both the 
intervention group and the true value of the outcome. Also, there were no sensitivity 
analyses conducted to test the robustness of study results to different assumptions 
about missing outcome data.
Trametinib
We judged the pivotal trial of trametinib to be at high risk of bias. In trial BRF113220, 
there was potential evidence of unbalanced censoring. According to the European 
public assessment report, there were relatively large proportions of censored 
participants in both trial arms. The censoring method included censoring for extended 
loss to follow-up, new anticancer therapy, and excluding symptomatic progression. 
While 31% of participants who received dabrafenib 150 mg were censored, 11% were 
censored among participants receiving trametinib. In the absence of evidence that 
results were robust to the presence of potentially missing outcome data (we were unable 
to find the results of “eight sensitivity analyses planned to investigate the robustness 
of progression-free survival against these censoring rules”), we concluded that this trial 
was at high risk of bias due to missing outcome data. In addition, local investigators in 
trial BRF113220 were unblinded and therefore aware of the intervention received by 
study participants. Because the assessment of the progression free survival outcome 
could be influenced by knowledge of the intervention received, the trial was also at 
high risk of bias owing to measurement of the outcome. The authors reported local 
results as their main analysis, although the results from the blinded review committee 
were also available in the main body of the publication. Results obtained from blinded 
assessment were less pronounced (hazard ratio for progression free survival was 0.39, 
95% confidence interval 0.25 to 0.62, according to local assessment, compared with 
0.55, 0.33 to 0.93).
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should be weighed against their several disadvantages. 
Firstly, patients might misinterpret such endpoints and 
overestimate the magnitude of benefit associated with 
new cancer drugs.82 83 Secondly, the strength of the 
correlation between surrogate and clinical outcomes 
in cancer trials is unclear.13 Over the past decade, 
several drugs (eg, bevacizumab in metastatic breast 
cancer)84 approved on the basis of surrogate measures 
failed to demonstrate overall survival gains in 
subsequent trials. In the recent BELLINI trial, patients 
who received venetoclax had shorter survival than 
those who received a control treatment (even though 
venetoclax appeared more effective than the control 
on the basis of progression free survival and response 
rate).59 Thirdly, and as recommended by regulators, 
unblinded trials (or trials at risk of unblinding) with 
surrogate endpoints might require additional (costly) 
safeguards such as independent blinded endpoint 
review to minimise risk of bias.63 Finally, and perhaps 
most importantly, evidence of overall survival benefit 
might never emerge for cancer drugs approved on 
the basis of surrogate measures alone.85 In an earlier 
study, we found that data on overall survival did not 
emerge in the postmarketing period for more than 90% 
of indications for which there was no evidence of such 
a benefit at the time of marketing authorisation.11
Taken together, these findings support more 
widespread use of overall survival as the primary 
endpoint in pivotal trials of new cancer drugs. 
Randomised controlled trials with overall survival 
endpoints were less likely to be at high risk of bias in 
our sample; this finding is consistent with an earlier 
assessment that showed that 66% of randomised 
controlled trials evaluating overall survival were at low 
risk of bias68 (the corresponding figure in our study 
was 80%). Overall survival would be largely immune 
to the risk of bias attributable to potential unblinding 
of outcome assessors and missing outcome data.22 26 27
There is also an opportunity to further improve 
the reporting standards of regulatory documents and 
scientific publications. Publication of the CONSORT 
statement in 1996 (and its update in 2010)46 has led 
to major improvements in randomised controlled trial 
reporting in the scientific literature.86 Also, the 2015 
revision87 of the European public assessment report 
template addressed some of the previous criticisms.88 
Currently, publications and regulatory documents 
make it difficult to distinguish between trial deficits 
that can be avoided and those that are more difficult 
to address. When methodological shortcomings 
are inevitable (eg, missing outcome data owing to 
withdrawal of participant consent), more transparent 
reporting is warranted. In addition, key information 
required to perform risk of bias assessments is still 
inconsistently reported in regulatory documents, trial 
protocols, publications, supplementary appendices, 
and clinical trials registries. For example, neither 
journal articles nor regulatory documents discuss the 
possibility that trial investigators could be unblinded 
when the adverse event profiles of comparator 
treatments are substantially different. Similarly, these 
sources do not consistently report the occurrence of 
protocol deviations that arose from the experimental 
context; whether deviations are balanced between 
the groups; and whether deviations could affect the 
outcome. Journal editors and European regulators 
can take further action to facilitate more complete 
and consistent reporting of pivotal studies.89 Our 
recommendations for improving the design, conduct, 
analysis, and reporting standards of cancer trials are 
listed in box 3.29
Limitations
Our study had several limitations. We did not include 
clinical study reports, which, according to previous 
reviews, might provide the most comprehensive set 
of information on randomised controlled trials.50 90 
Because there is no established guidance on how to 
feasibly collect information from such reports, their use 
in systematic reviews remains limited.91 92 We focused 
on cancer drug trials, therefore the generalisability 
of our findings to trials in other therapeutic areas 
is unclear. Nevertheless, cancer drugs comprise the 
single largest category of recent drug approvals.93  94 
Additionally our study included cancer drug 
approvals between 2014 and 2016; characteristics 
of randomised controlled trials that supported EMA 
approvals during our study period might not reflect 
the design, conduct, analysis, and reporting of cancer 
drug trials outside of this period. Furthermore, our risk 
of bias assessments were not blinded to study results 
because risk of bias assessments require examination 
of results. However, a systematic review of randomised 
trials did not identify evidence overall of a difference in 
risk of bias judgments between blinded and unblinded 
assessments.95
Box 3: Recommendations to improve the design, conduct, analysis, and reporting 
of pivotal trials of new cancer drugs
• Because overall survival would be largely immune to several sources of potential bias, 
regulators should require overall survival to be the primary endpoint of pivotal trials.
• Other desirable trial endpoints include quality of life and measures with established 
surrogacy.
• The magnitude of benefit associated with new cancer therapies should be carefully 
considered in trial design.
• When subjectively assessed outcomes are used as primary endpoints, trial sponsors 
should implement blinded independent central review of tumour assessments.
• If the trial is blinded, trial sponsors and investigators should adopt strategies to 
avoid unblinding of investigators, for example centralised dosage modification of 
treatments; this is especially important when outcome assessment is not blinded.
• Trial sponsors and investigators should report the risk of unblinding in trials in which 
investigators are not aware of treatment allocation; this is especially important when 
outcome assessment is not blinded.
• Trial sponsors and investigators should conduct sensitivity analyses to evaluate the 
robustness of trial results to missing outcome data. Regulators and journal editors 
should require consistent reporting of the findings of these sensitivity analyses.
• Regulators and journal editors should require consistent reporting of any major 
deviations from intended interventions that arose from the experimental context; 
whether deviations are balanced between the groups; and whether deviations could 
affect the outcome.
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We examined the risk of bias, rather than bias itself. 
Therefore, it remains a possibility that trial results are 
unbiased despite the methodological flaws identified 
in our assessments. According to previous studies, 
risk of bias judgments based on publications alone 
might rely on incomplete information,50 and might not 
reflect the true methodological rigour of underlying 
studies.69  70 To address this issue, we relied on a 
combination of regulatory documents, trial protocols, 
publications, supplementary materials, and clinical 
trials registries. In some cases, our judgments were 
substantiated with potential evidence of bias; for 
instance, when outcome measurements available from 
unblinded local investigators produced exaggerated 
findings compared with those obtained from an 
independent panel of masked assessors. For example, 
the magnitude of progression free survival benefit 
reported in the BRF113220 trial was less pronounced 
when assessed by an independent committee than 
by investigators (hazard ratio 0.39 v 0.55).96 Notably, 
our findings do not imply that EMA decisions are 
biased, and they do not suggest that pharmaceutical 
manufacturers deliberately introduce bias into their 
trials. Instead, our findings identify methodological 
shortcomings in pivotal trials of new cancer drugs.
Finally, our assessments focused on the primary 
endpoints of randomised controlled trials; it remains 
possible that results for other outcomes could be at 
lower risk of bias. However, this is unlikely because 
pervasive limitations are well documented for 
secondary endpoints of cancer drug trials, including 
harms97-99 and quality of life outcomes.100 101 
Therefore, we might not have fully captured other 
important shortcomings of randomised controlled 
trials that support cancer drug approvals.
Conclusions
Most pivotal studies that formed the basis of EMA 
approval of new cancer drugs between 2014 and 2016 
used randomised designs. Despite the widely accepted 
strengths of such designs, we concluded that almost 
half of randomised controlled trials were at high risk 
of bias because of deficits in their design, analysis, and 
conduct. During our study period, European regulators 
identified other concerns for 7 out of 16 drugs that had 
at least one randomised controlled trial at low risk of 
bias. Journal publications did not acknowledge the key 
trial limitations identified in regulatory documents. 
Policymakers, investigators, and clinicians should 
carefully consider risks of bias in pivotal trials that 
support regulatory decisions, and the extent to which 
new cancer therapies offer meaningful benefit to 
patients.
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